Diagnosis of Friedreich Ataxia

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the process of definitive diagnosis through genetic testing, and the significant emotional and practical impact that such a diagnosis has on affected families.

EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

EP: 5.Examining Trial Data on Omaveloxolone Efficacy

EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia

EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape

EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Now Viewing

EP: 9.Diagnosis of Friedreich Ataxia

EP: 10.Impact of Friedreich Ataxia on Quality of Life

EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale

EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia

EP: 13.Challenges Associated With Friedreich Ataxia

EP: 14.Future Considerations for Friedreich Ataxia

Video content above is prompted by the following:

Could you elaborate on the differential diagnosis for this disease, how it is definitively diagnosed and the impact of receiving such a diagnosis for families? 

Related Videos

Related Content

Advertisement

March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

February 26th 2025

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease

Giuliana Grossi

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

February 4th 2025

FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease

Skylar Jeremias

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.

January 30th 2025

New Model Predicts Stroke Severity and Improves Functional Independence

Cameron Santoro

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.

January 28th 2025

EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD

Rose McNulty

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years in patients with Duchenne muscular dystrophy (DMD).

Related Content

Advertisement

March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

February 26th 2025

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease

Giuliana Grossi

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

February 4th 2025

FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease

Skylar Jeremias

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.

January 30th 2025

New Model Predicts Stroke Severity and Improves Functional Independence

Cameron Santoro

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.

January 28th 2025

EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD

Rose McNulty

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years in patients with Duchenne muscular dystrophy (DMD).